Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Blood|October 25, 2001
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosisA Kaser, G Brandacher, W Steurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelinesK A Margolin, A A Rayner, M J Hawkins, et al.
Blood|November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma productionJ P Leonard, M L Sherman, G L Fisher, et al.
Journal of Clinical Immunology|November 1, 1988
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJ W Mier, G Vachino, J W van der Meer, et al.
British Journal of Cancer|June 16, 2011
Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinomaR S Bhatt, A J Zurita, A O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993M B Atkins, M T Lotze, J P Dutcher, et al.
ESMO Open|February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>A A Tarhini, K Toor, K Chan, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicityJ A Sosman, F R Aronson, M Sznol, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Blood|October 25, 2001
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosisA Kaser, G Brandacher, W Steurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelinesK A Margolin, A A Rayner, M J Hawkins, et al.
Blood|November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma productionJ P Leonard, M L Sherman, G L Fisher, et al.
Journal of Clinical Immunology|November 1, 1988
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJ W Mier, G Vachino, J W van der Meer, et al.
British Journal of Cancer|June 16, 2011
Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinomaR S Bhatt, A J Zurita, A O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993M B Atkins, M T Lotze, J P Dutcher, et al.
ESMO Open|February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>A A Tarhini, K Toor, K Chan, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicityJ A Sosman, F R Aronson, M Sznol, et al.
Pageof 11